Lotte Biologics Amends Capital Increase Details
롯데지주
004990
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2767
Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares Issued: 4,208,111 Shares (Ordinary Shares)
- • Capital Raised: 255,255,597,038 KRW
- • Issue Price per Share: 60,658 KRW
- • Pre-increase Shares: 18,292,169 Shares
- • Dilution Rate: Approximately 23.00985%
AI Analysis Summary
Lotte Corporation's subsidiary, Lotte Biologics Co., Ltd., amended its paid-in capital increase details. The number of new ordinary shares issued was adjusted from 4,209,000 to 4,208,111 shares, and the capital raised for facility funds changed from 255,309,522,000 KRW to 255,255,597,038 KRW. The amendment reflects the non-issuance of 889 forfeited shares. The capital increase, via a shareholder allocation method, aims to fund the construction of the Songdo Bio Campus Plant 1. The issue price is 60,658 KRW per share, leading to a dilution of approximately 23.00985% for existing shareholders. The overall impact is neutral as the amendment clarifies previously announced plans.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.